A Study of a Novel Precision Medicine Approach For Obesity
NCT06814938 on ClinicalTrials.gov · last registry update 2026-07-16
Closed to new participants; the 135 already enrolled are still being followed. Due to report December 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Change in Total Body Weight at 24 weeks. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Mayo Clinic
- Sponsor type
- Other
- Enrollment
- 135
- Started
- 2025-02-21
- Primary completion
- 2027-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Total Body Weight at 24 weeks
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.